(0.23%) 5 111.74 points
(0.20%) 38 315 points
(0.25%) 15 967 points
(-1.09%) $82.94
(4.99%) $2.02
(0.11%) $2 349.70
(0.16%) $27.58
(4.14%) $960.30
(-0.17%) $0.933
(-0.30%) $10.99
(-0.45%) $0.797
(1.74%) $93.47
@ $11.35
Utstedt: 14 feb 2024 @ 15:30
Avkastning: -3.70%
Forrige signal: feb 13 - 15:30
Forrige signal:
Avkastning: 3.37 %
Live Chart Being Loaded With Signals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers...
Stats | |
---|---|
Dagens volum | 80 006.00 |
Gjennomsnittsvolum | 829 708 |
Markedsverdi | 775.59M |
EPS | $0 ( 2024-03-06 ) |
Neste inntjeningsdato | ( $-0.850 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.45 |
ATR14 | $0.0300 (0.27%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Vultaggio Vincent | Sell | 0 | Common Stock |
2024-04-05 | Vultaggio Vincent | Sell | 12 500 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 10 000 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 6 875 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 2 750 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
85.13 |
Last 97 transactions |
Buy: 9 826 125 | Sell: 711 798 |
Volum Korrelasjon
Zentalis Pharmaceuticals Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner | |
---|---|
RAVN | -0.813 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Zentalis Pharmaceuticals Korrelasjon - Valuta/Råvare
Zentalis Pharmaceuticals Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-1.39M (0.00 %) |
EPS: | $-4.47 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-1.39M (0.00 %) |
EPS: | $-4.47 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $-1.43M (0.00 %) |
EPS: | $-4.18 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-5.65 |
Financial Reports:
No articles found.
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.